Analysts expect Sanofi to report revenue of 55.48 B for 2026, against a range of 50.47 B to 60.48 B. The most recent reported year, 2025, came in at 55.09 B, a 0.4% miss against the 55.31 B consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 43.21 B | 49.28 B | 46.64 B | 46.21 B | 55.09 B | - | - | ||
| High Estimate | 45.94 B | 47.43 B | 51.25 B | 51.42 B | 57.27 B | 60.48 B | 68.56 B | ||
| Low Estimate | 38.81 B | 44.42 B | 42.71 B | 45.13 B | 53.34 B | 50.47 B | 58.55 B | ||
| Consensus Estimate | 42.37 B | 45.93 B | 46.98 B | 48.28 B | 55.31 B | 55.48 B | 63.55 B |
Analysts expect Sanofi to report earnings per share of 4.65 for 2026, against a range of 4.31 to 4.99. The most recent reported year, 2025, came in at 4.67, a 3.3% miss against the 4.83 consensus.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 3.73 | 4.48 | 4.39 | 3.71 | 4.67 | - | - | ||
| High Estimate | 3.70 | 5.13 | 4.66 | 4.01 | 5.17 | 4.99 | 5.36 | ||
| Low Estimate | 3.20 | 4.25 | 3.98 | 3.33 | 4.49 | 4.31 | 4.46 | ||
| Consensus Estimate | 3.45 | 4.69 | 4.32 | 3.67 | 4.83 | 4.65 | 4.91 |